H.C. Wainwright on Jasper Therapeutics (JSPR): 'We believe briquilimab data bode well competitively'
Tweet Send to a Friend
H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $40.00 price target on Jasper Therapeutics (NASDAQ: JSPR)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
